ACTU Stock Summary and Trading Ideas (Actuate Therapeutics | NASDAQ:ACTU)

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

Actuate Therapeutics trades on the NASDAQ stock market under the symbol ACTU.

As of July 17, 2026, ACTU stock price declined to $1.56 with 70,846 million shares trading.

ACTU has a beta of 2.00, meaning it tends to be more sensitive to market movements. ACTU has a correlation of 0.07 to the broad based SPY ETF.

ACTU has a market cap of $37.32 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that ACTU belongs to (by Net Assets): VTI, VXF, IWC.

ACTU has underperformed the market in the last year with a return of -75.0%, while the SPY ETF gained +20.4%. In the last 3 month period, ACTU fell short of the market, returning -27.4%, while SPY returned +6.3%. However, in the most recent 2 weeks ACTU has outperformed the stock market by returning +2.6%, while SPY returned -0.1%.

ACTU support price is $1.50 and resistance is $1.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACTU shares will trade within this expected range on the day.